Characterization of Asciminib-Resistant Philadelphia Chromosome-Positive Cells.
World J Oncol
; 15(2): 319-324, 2024 Apr.
Article
en En
| MEDLINE
| ID: mdl-38545482
ABSTRACT
Background:
Asciminib is approved for treating patients with chronic-phase chronic myeloid leukemia who were previously treated with two or more tyrosine kinase inhibitors or those with T315I mutation. However, the mechanisms underlying asciminib resistance remain unclear.Methods:
In this study, we established a new asciminib-resistant cell line. We examined BCRABL1 gene mutation analysis and the effects of conventional chronic myelogenous leukemia inhibitors.Results:
Direct sequencing revealed Y139D and T315I mutations in asciminib-resistant cells. Ponatinib and omacetaxine were effective against asciminib-resistant cells.Conclusions:
Y139D and T315I mutations are extremely resistant to asciminib. Ponatinib and omacetaxine show potential for treating asciminib-resistant chronic myeloid leukemia.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Año:
2024
Tipo del documento:
Article